Bayer AG has experienced a remarkable turnaround in 2025, with stock prices climbing nearly 40%, marking it as one of the DAX's top performers. This rebound is fueled by optimism regarding a resolution to its long-standing litigation over Roundup weedkiller and the potential success of its new stroke prevention drug, Asundexian. Despite its troubles from past decisions, including costly claims from its 2018 Monsanto acquisition, analysts are beginning to see a brighter future. Chief Executive Officer Bill Anderson's focus on streamlining operations and legal strategies might be paying off, as more investors speculate on positive legal outcomes from the Supreme Court.
The entire situation for Bayer is definitely better than last year. The first successes of the turnaround are visible.
There’s probably a 40% chance that the Supreme Court will carry out the review of the Roundup litigation.
Collection
[
|
...
]